Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders |
| |
| Institution: | 1. Department of Radiology, Centre du Cancer and Institut de Recherche Expérimentale et Clinique (IREC–IMAG), Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCL), Avenue Hippocrate 10/2942, Brussels B-1200, Belgium;2. Department of Nuclear Medicine, Centre du Cancer and Institut de Recherche Expérimentale et Clinique (IREC–IMAG), Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCL), Avenue Hippocrate 10/2942, Brussels B-1200, Belgium;3. Department of Radiology, Boston University School of Medicine, 820 Harrison Avenue, FGH Building, 3rd floor, Boston, MA 02118, USA;1. Department of Surgery, Rijnstate Hospital, Wagnerlaan 55, 6815 AD Arnhem, the Netherlands;2. Department of Radiology, Rijnstate Hospital, Wagnerlaan 55, 6815 AD Arnhem, the Netherlands;3. Department of Health Technology and Services Research, Technical Medical Center, University of Twente, Drienerlolaan 5, 7522 NB Enschede, the Netherlands;4. Department of Surgical Oncology, Radboud University Medical Center Nijmegen, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands;5. Department of Surgery, Rijnstate Hospital, Wagnerlaan 55, 6815 AD Arnhem, the Netherlands;6. Department of Radiology and Nuclear Medicine, Radboud University Nijmegen Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands;1. Department of Hematology, Ankara University School of Medicine, Cebeci Research and Application Hospital, Mamak, Amkara 06590, Turkey;2. Department of Nuclear Medicine, Ankara University School of Medicine, Cebeci Research and Application Hospital, Mamak, Amkara 06590, Turkey |
| |
| Abstract: | Fluorine-18 (18F)-fluorodeoxyglucose (FDG) positron emission tomography (PET) allows evaluation of elevated glucose metabolism in malignancies. There has been increasing interest in FDG PET/CT for plasma cell disorders since the International Myeloma Working Group outlined multiple applications of this imaging modality, including distinguishing smoldering myeloma from active multiple myeloma, confirmation of solitary plasmacytoma, and multiple indications in patients with known multiple myeloma, including determining extent of initial disease, monitoring therapy response, and detection of residual disease following therapy. The field of molecular imaging is now shifting focus from evaluation of metabolism to targeted evaluation of specific tumor markers. Targeted PET imaging targeted of CXCR4 and CD38 has advanced into translational clinical trials, bringing us closer to powerful imaging options for myeloma. In this review we discuss the current applications of FDG PET/CT in plasma cell disorders, as well as advances in targeted PET imaging. |
| |
| Keywords: | Positron emission tomography (PET) Multiple myeloma 18F-fluorodeoxyglucose (FDG) immunoPET |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
